Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives $99.11 Consensus PT from Brokerages

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have been assigned a consensus rating of “Moderate Buy” from the fourteen ratings firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $99.1111.

GPCR has been the topic of a number of research analyst reports. Morgan Stanley raised their price target on Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Wednesday, October 8th. Lifesci Capital raised shares of Structure Therapeutics to a “strong-buy” rating in a research note on Monday, September 8th. Jefferies Financial Group set a $125.00 price target on shares of Structure Therapeutics and gave the company a “buy” rating in a report on Thursday, December 11th. Finally, Zacks Research downgraded shares of Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, October 17th.

Institutional Trading of Structure Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Balyasny Asset Management L.P. bought a new stake in shares of Structure Therapeutics in the third quarter valued at about $12,923,000. Pacific Heights Asset Management LLC acquired a new stake in Structure Therapeutics in the 2nd quarter valued at approximately $9,540,000. Orbimed Advisors LLC lifted its stake in Structure Therapeutics by 49.5% in the 2nd quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock valued at $24,873,000 after acquiring an additional 397,272 shares in the last quarter. Paradigm Biocapital Advisors LP bought a new stake in Structure Therapeutics in the 3rd quarter valued at approximately $10,440,000. Finally, Casdin Capital LLC boosted its position in Structure Therapeutics by 26.9% during the 3rd quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock worth $43,540,000 after acquiring an additional 330,000 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Stock Down 1.9%

Shares of GPCR stock opened at $68.34 on Thursday. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $94.90. The firm has a fifty day moving average of $42.84 and a 200-day moving average of $28.88. The firm has a market capitalization of $4.15 billion, a price-to-earnings ratio of -56.02 and a beta of -1.64.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.01). Research analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.